Viking Therapeutics Inc (VKTX) has a current Price-to-Book (P/B) ratio of 5.59. Compared to its 3-year average P/B ratio of 6.47, the current P/B ratio is approximately -13.61% higher. Relative to its 5-year average P/B ratio of 4.63, the current P/B ratio is about 20.54% higher. Viking Therapeutics Inc (VKTX) has a Forward Free Cash Flow (FCF) yield of approximately -5.61%. Compared to its 3-year average FCF yield of -3.20%, the current FCF yield is approximately 75.05% lower. Relative to its 5-year average FCF yield of -7.35%, the current FCF yield is about -23.68% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for VKTX competitors is 19.60, providing a benchmark for relative valuation. Viking Therapeutics Inc Corp (VKTX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of VKTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of VKTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is VKTX currently overvalued or undervalued?

What is Viking Therapeutics Inc (VKTX) fair value?

VKTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Viking Therapeutics Inc (VKTX) is between to according to relative valuation method.

How does VKTX's valuation metrics compare to the industry average?

The average P/S ratio for VKTX's competitors is 19.60, providing a benchmark for relative valuation. Viking Therapeutics Inc Corp (VKTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Viking Therapeutics Inc (VKTX) as of Mar 03 2026?

As of Mar 03 2026, Viking Therapeutics Inc (VKTX) has a P/B ratio of 5.59. This indicates that the market values VKTX at 5.59 times its book value.

What is the current FCF Yield for Viking Therapeutics Inc (VKTX) as of Mar 03 2026?

As of Mar 03 2026, Viking Therapeutics Inc (VKTX) has a FCF Yield of -5.61%. This means that for every dollar of Viking Therapeutics Inc's market capitalization, the company generates -5.61 cents in free cash flow.

What is the current Forward P/E ratio for Viking Therapeutics Inc (VKTX) as of Mar 03 2026?

As of Mar 03 2026, Viking Therapeutics Inc (VKTX) has a Forward P/E ratio of -9.13. This means the market is willing to pay $-9.13 for every dollar of Viking Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Viking Therapeutics Inc (VKTX) as of Mar 03 2026?

As of Mar 03 2026, Viking Therapeutics Inc (VKTX) has a Forward P/S ratio of 0.00. This means the market is valuing VKTX at $0.00 for every dollar of expected revenue over the next 12 months.

VKTX Valuation